proposal also involves the acquisition of a nonbanking company, the review also includes whether the acquisition of the nonbanking company complies with the standards in section 4 of the BHC Act (12 U.S.C. 1843). Unless otherwise noted, nonbanking activities will be conducted throughout the United States. Additional information on all bank holding companies may be obtained from the National Information Center website at *www.ffiec.gov/nic/*.

Unless otherwise noted, comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than November 13, 2003.

A. Federal Reserve Bank of St. Louis (Randall C. Sumner, Vice President) 411 Locust Street, St. Louis, Missouri 63166-2034:

1. Freedom Bancshares of Southern Missouri, Inc., Cassville, Missouri; to become a bank holding company by acquiring 100 percent of the voting shares of Freedom Bank of Southern Missouri, Cassville, Missouri.

Board of Governors of the Federal Reserve System, October 14, 2003.

Robert deV. Frierson,

Deputy Secretary of the Board.

[FR Doc. 03–26405 Filed 10–17–03; 8:45 am]

BILLING CODE 6210–01–S

FEDERAL RESERVE SYSTEM

Sunshine Act Notice

AGENCY HOLDING THE MEETING: Board of Governors of the Federal Reserve System.

TIME AND DATE: 10 a.m., Wednesday, October 22, 2003.

PLACE: Marriner S. Eccles Federal Reserve Board Building, 20th Street entrance between Constitution Avenue and C Streets, NW., Washington, DC 20551.

STATUS: Open.

We ask that you notify us in advance if you plan to attend the open meeting and provide your name, date of birth, and social security number (SSN) or passport number. You may provide this information by calling (202) 452–2474 or you may *register on-line.* You may pre-register until close of business October 21, 2003. You also will be asked to provide identifying information, including a photo ID, before being admitted to the Board meeting. The Public Affairs Office must approve the use of cameras; please call (202) 452–2955 for further information.

Privacy Act Notice: Providing the information requested is voluntary; however, failure to provide your name, date of birth, and social security number or passport number may result in denial of entry to the Federal Reserve Board. This information is solicited pursuant to Sections 10 and 11 of the Federal Reserve Act and will be used to facilitate a search of law enforcement databases to confirm that no threat is posed to Board employees or property. It may be disclosed to other persons to evaluate a potential threat. The information also may be provided to law enforcement agencies, courts and others, but only to the extent necessary to investigate or prosecute a violation of law.

MATTERS TO BE CONSIDERED:

Summary Agenda: Because of its routine nature, no discussion of the following item is anticipated. The matter will be voted on without discussion unless a member of the Board requests that the item be moved to the discussion agenda.

1. Proposed 2004 Private Sector Adjustment Factor.

Discussion Agenda

2. Proposed revisions to the method for imputing earnings on clearing balance investments.

3. Proposed 2004 fee schedules for priced services and electronic connections.

4. Any items carried forward from a previously announced meeting.

Note: This meeting will be recorded for the benefit of those unable to attend. Cassettes will be available for listening in the Board's Freedom of Information Office and copies may be ordered for $6 per cassette by calling 202–452–3684 or by writing to: Freedom of Information Office, Board of Governors of the Federal Reserve System, Washington, DC 20551.

FOR FURTHER INFORMATION CONTACT: Michelle A. Smith, Director, Office of Board Members; 202–452–2955.

SUPPLEMENTARY INFORMATION: You may call 202–452–3206 for a recorded announcement of this meeting; or you may contact the Board's Web site at *http://www.federalreserve.gov* for an electronic announcement. (The Web site also includes procedural and other information about the open meeting.)

Dated: October 15, 2003.

Robert deV. Frierson,

Deputy Secretary of the Board.

[FR Doc. 03–26553 Filed 10–16–03; 2:34 pm]

BILLING CODE 6210–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

National Center on Birth Defects and Developmental Disabilities; Meeting

NAME: Newborn Screening for Cystic Fibrosis (CF).

TIMES AND DATES: 8 a.m.–5:30 p.m., November 20, 2003. 7:50 a.m.–4 p.m., November 21, 2003.

PLACE: Renaissance Atlanta Hotel Downtown, 590 West Peachtree Street NW., Atlanta, Georgia 30308–3586, Telephone (404) 881–6000.

STATUS: Open to the public, limited only by the space available.

PURPOSE: The meeting will review the recommendations from the 1997 Newborn Screening for Cystic Fibrosis: A Paradigm for Public Health Genetics Policy Workshop, and will evaluate the current evidence examining the benefits and risks of screening newborns for CF. In addition, the meeting will review the role of screening, diagnostics, and follow-up issues in CF newborn screening decision-making.

MATTERS TO BE DISCUSSED: The agenda will include an overview of newborn screening; the role of evidence based decision-making; the epidemiology and natural history of the disease; a review of the published and unpublished literature assessing the risks and benefits of screening newborns for CF; discussion about grading the evidence; weighting risks and benefits; planning challenges; screening issues; informed consent; diagnostics and sweat testing referrals, linking screening programs with CF centers for care of diagnosed infants; implications for state programs considering screening; communication; costs; and the evidence to support a public health response to CF newborn screening.

Agenda items are subject to change as priorities dictate.

FOR FURTHER INFORMATION CONTACT: Scott Grosse, Ph.D., National Center on Birth Defects and Developmental Disabilities, CDC, 1600 Clifton Road, NE, m/s E–87, Atlanta, Georgia 30333, telephone 404/498–3074.

The Director, Management Analysis and Services office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities for both CDC and the Agency for Toxic Substances and Disease Registry.

Dated: October 9, 2003.

Alvin Hall,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 03–26270 Filed 10–17–03; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 2003N–0102]

Robert Ray Courtney; Debarment Order

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is issuing an order under the Federal Food, Drug, and Cosmetic Act (the act) permanently debarring Robert Ray Courtney from providing services in any capacity to a person that has an approved or pending drug product application. FDA bases this order on a finding that Mr. Courtney was convicted of a felony under Federal law for conduct otherwise relating to the regulation of any drug product under the act. Mr. Courtney failed to request a hearing and, therefore, has waived his opportunity for a hearing concerning this action.

DATES: This order is effective October 20, 2003.

ADDRESSES: Submit applications for termination of debarment to the Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852.

FOR FURTHER INFORMATION CONTACT: Nicole K. Mueller, Center for Drug Evaluation and Research (HFD–7), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–594–2041.

SUPPLEMENTARY INFORMATION:

I. Background

On February 26, 2002, Mr. Robert Ray Courtney entered into an agreement pleading guilty to eight counts of tampering with consumer products in violation of 18 U.S.C. 1365(a) and (a)(3), and six counts each of misbranding and adulterating drugs in violation of sections 301(k) and 303(a)(2) of the act (21 U.S.C. 331(k) and 333(a)(2)). On December 5, 2002, the U.S. District Court for the Western District of Missouri sentenced Mr. Courtney to the maximum 30 years in prison and required Mr. Courtney to pay a fine of $25,000 and $10.4 million in restitution for diluting drugs he dispensed to his pharmacy customers. Such drugs included the chemotherapy medications Gemzar (gemcitabine) and Taxol (paclitaxel).

At the time of Mr. Courtney's criminal actions, he was a pharmacist and owner of Courtney Pharmacy, Inc., d/b/a Research Medical Tower Pharmacy, a company that operated two pharmacies: Research Medical Tower Pharmacy in Kansas City, MO, and Courtney Pharmacy in Overland Park, KS. Among other things, Mr. Courtney was responsible for mixing, preparing, labeling, and distributing intravenous drug mixtures.

In 2001, the Federal Bureau of Investigations (FBI) and FDA set up an investigation that revealed that certain medications Mr. Courtney dispensed were far less potent than the medications ordered by prescribing physicians. One drug sample contained less than 1 percent of the prescribed amount. The investigation resulted in the filing of a complaint on August 14, 2001, charging Mr. Courtney with adulteration and misbranding. It was eventually determined that more than 4,000 patients may have had their prescriptions diluted by Mr. Courtney over a 10-year period. The investigation and admissions by Mr. Courtney culminated in his guilty plea to all 20 counts of the indictment.

As a result of this conviction, FDA served Mr. Courtney by certified mail on May 16, 2003, a notice proposing to permanently debar him from providing services in any capacity to a person that has an approved or pending drug product application. The proposal also offered Mr. Courtney an opportunity for a hearing on the proposal. The proposal was based on a finding, under section 306(a)(2)(B) of the act (21 U.S.C. 335a(a)(2)(B)), that Mr. Courtney was convicted of a felony under Federal law for conduct otherwise relating to the regulation of any drug product under the act. Mr. Courtney was provided 30 days to file objections and request a hearing. Mr. Courtney did not request a hearing. His failure to request a hearing constitutes a waiver of his opportunity for a hearing and a waiver of any contentions concerning his debarment.

II. Findings and Order

Therefore, the Director, Center for Drug Evaluation and Research, under section 306(a)(2)(B) of the act, and under authority delegated to her (21 CFR 5.34), finds that Mr. Robert Ray Courtney has been convicted of a felony under Federal law for conduct otherwise relating to the regulation of any drug product under the act.

As a result of the foregoing finding, Mr. Robert Ray Courtney is permanently debarred from providing services in any capacity to a person with an approved or pending drug product application under sections 505, 512, or 802 of the act (21 U.S.C. 355, 360b, or 382), or under section 351 of the Public Health Service Act (42 U.S.C. 262), effective October 20, 2003 (see sections 306(c)(1)(B) and (c)(2)(A)(ii) and 201(dd) of the act (21 U.S.C. 321(dd))). Any person with an approved or pending drug product application who knowingly uses the services of Mr. Courtney, in any capacity, during his period of debarment, will be subject to civil money penalties (section 307(a)(6) of the act (21 U.S.C. 335b(a)(6))). If Mr. Courtney, during his period of debarment, provides services in any capacity to a person with an approved or pending drug product application, he will be subject to civil money penalties (section 307(a)(7) of the act). In addition, FDA will not accept or review any abbreviated new drug applications submitted by or with the assistance of Mr. Courtney during his period of debarment.

Any application by Mr. Courtney for termination of debarment under section 306(d)(4) of the act should be identified with Docket No. 03N–0102 and sent to the Division of Dockets Management (see **ADDRESSES**). All such submissions are to be filed in four copies. The public availability of information in these submissions is governed by 21 CFR 10.20(j). Publicly available submissions may be seen in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday.

Dated: October 1, 2003.

Janet Woodcock,

Director, Center for Drug Evaluation and Research.

[FR Doc. 03–26385 Filed 10–17–03; 8:45 am]

BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Factor VIII Inhibitors; Public Workshop

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of public workshop.

The Food and Drug Administration (FDA) is announcing a public workshop entitled ''Factor VIII Inhibitors.'' The purpose of the public workshop is to provide a forum for addressing